)
Visual
earnings real time
Biohaven
Biohaven (BHVN) investor relations material
Biohaven Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary10 Nov, 2025
Executive summary
Focused on immunology, neuroscience, and oncology, with reprioritization to three key clinical programs: Kv7 ion channel modulation, MODE/TRAP protein degraders, and myostatin-activin pathway agents, including opakalim, BHV-1300, and BHV-1400.
Advanced late-stage clinical programs in epilepsy, depression, autoimmune disease, obesity, and cancer, with several Phase 1–3 trials ongoing or planned.
Initiated strategic cost optimization, prioritizing high-value programs and reducing annual direct R&D spend by approximately 60%.
Restructured business priorities, pausing or halting non-priority programs to optimize resource allocation.
No product revenue to date; operations funded by equity and debt, including a $250M note issuance in April 2025.
Financial highlights
Net loss of $173.4M for Q3 2025 ($1.64 per share), compared to $160.3M in Q3 2024; net loss of $593.3M for the nine months ended September 30, 2025.
R&D expenses were $141.2M in Q3 2025 (down $16.4M YoY), and $513.1M for the nine months (down $115.3M YoY, mainly due to a one-time $171.9M expense in 2024 for a milestone/royalty buyback).
G&A expenses increased to $28.2M in Q3 2025 (up $7.7M YoY), and $89.5M for the nine months (up $22.7M YoY), driven by higher share-based compensation and legal costs.
Cash, cash equivalents, marketable securities, and restricted cash totaled $263.8M as of September 30, 2025.
Non-GAAP adjusted net loss for Q3 2025 was $155.9M ($1.47 per share), compared to $164.1M ($1.74 per share) in Q3 2024.
Outlook and guidance
Cash, equivalents, marketable securities, and equity commitments expected to fund operations for at least one year from issuance.
Additional capital will be required to execute business plans and pursue growth; future funding may come from equity, debt, or strategic transactions.
Top-line results from Phase 2 study of opakalim in major depressive disorder expected in Q4 2025.
Initial top-line results from two Phase 2/3 studies in focal epilepsy anticipated in 1H 2026.
Phase 2 clinical trial for taldefgrobep alfa in obesity to begin in Q4 2025.
Projected net R&D spend after optimization
Discuss SCA appeal process viability
Cash runway considering new debt and R&D cuts
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- IEX
Record HST orders and margin gains support 2026 growth outlook amid macro uncertainties. - PFGC
Q2 and first-half 2026 saw 5.2% sales growth and 45.5% higher net income, with updated guidance. - CB
Record earnings, premium growth, and strong outlook driven by digital and global expansion. - COR
Q1 FY2026 revenue up 5.5% to $85.9B; adjusted EPS rose 9.4% to $4.08. - MATW
Leverage below 3x, Q1 net income $43.6M, FY2026 EBITDA guidance at $180M. - SU
Record production, strong cash returns, and robust 2026 guidance highlight performance. - GARAN
Net income up 21% to TL 111.3bn, with strong capital, liquidity, and asset growth. - ABBV
Record $61.2B sales, $10.00 EPS, and 2026 EPS guidance of $14.37–$14.57. - IAC
Q4 2025 digital revenue up 14%, Adjusted EBITDA up 29%, and $337M in share buybacks. - VLTO
Record 2025 growth and cash flow, with 2026 set for further gains and margin expansion.
Next Biohaven earnings date
Q4 202527 Feb, 2026
Biohaven
Next Biohaven earnings date
Q4 202527 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. The company's product candidates are either in various stages of clinical trials or pre-clinical trials.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage